Plain-English translation of NCT07192341 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a medication called in people who have had heart valve replacement surgery and now have a weakened heart. The medication is already approved by the FDA to treat heart failure in other patients, and this trial wants to see if it works safely and effectively for people with artificial valves. Researchers will compare patients taking this medication alongside their regular heart treatments with patients receiving only standard care.
Heart failure is becoming more common, and people who have had artificial heart valves are at higher risk for developing it. This medication has shown promise in helping heart failure patients overall, but doctors don't yet know if it's safe or beneficial specifically for people with prosthetic valves.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to one of two groups: one group will take the medication by mouth twice daily (starting at a low dose and gradually increasing), while the other group will continue only their usual heart medications. You'll have regular follow-up visits where doctors will check your blood pressure, heart function, and overall health. The trial involves 220 patients total and will continue for a set period while researchers track how well you're doing and how the medication affects your symptoms.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Egypt
Sponsor
Kafrelsheikh University
Enrollment target
~220 participants
Started
September 2025
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mohammed A Hammad, MD
Kafrelsheikh University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.